In 2011, a group of entrepreneurs invested in a philanthropic effort to treat cancer via this discovery. Together with the inventor of the original ISCOM technology, the group created a business structure, bringing in additional expertise and founded several companies focused to exploiting the patent portfolio in cancer therapy.